Journal of clinical practice and research · 2025
Impact of Induction Therapy on Preventing Early Acute Kidney Allograft Rejection: A Single-Center Experience Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kumru Gizem, Eyupoglu Sahin, Sendogan Damla Ors, Kocaay Akin Firat, Tuzuner Acar, Sengul Sule, Keven Kenan
Аннотация
OBJECTIVE: Acute rejection infrequently occurs among immunologically low-risk recipients within the first few weeks after transplantation, and the role of induction treatment in the frequency of acute rejection and graft loss remains debatable.
MATERIALS AND METHODS: This retrospective study analyzed 208 kidney transplant recipients with low immunological risk, defined by living donor transplantation, no prior transplantation history, absence of preformed anti-HLA antibodies, and a negative lymphocyte crossmatch prior to transplantation. Demographic data, immunologic characteristics, and graft functions were analyzed concerning early acute rejection history.
RESULTS: Fifteen patients (7.2%) experienced acute rejection within two weeks post-transplantation. No correlation was found between the number of HLA mismatches and induction treatment with early acute rejection. The cumulative incidences of acute rejection in the no-induction and basiliximab groups were comparable at 7.8% and 6.4%, respectively. Donor age was markedly higher, and the tacrolimus trough level on the seventh day post-transplantation was significantly lower in the early acute rejection group; however, the significance was lost after adjustment. The incidence of graft loss was higher in the early acute rejection cohort than in the no-rejection cohort (33.3% vs. 3.1%, p<0.001). Early acute rejection was the only independent risk factor for graft failure (HR 10.286, CI 1.944-54.409, p=0.006).
CONCLUSION: Acute rejection within two weeks post-transplantation has been associated with suboptimal graft function in recipients with low immunological risk. Basiliximab does not provide additional advantages in preventing early acute rejection in patients with a low immunological risk on tacrolimus-based immunosuppression.
MATERIALS AND METHODS: This retrospective study analyzed 208 kidney transplant recipients with low immunological risk, defined by living donor transplantation, no prior transplantation history, absence of preformed anti-HLA antibodies, and a negative lymphocyte crossmatch prior to transplantation. Demographic data, immunologic characteristics, and graft functions were analyzed concerning early acute rejection history.
RESULTS: Fifteen patients (7.2%) experienced acute rejection within two weeks post-transplantation. No correlation was found between the number of HLA mismatches and induction treatment with early acute rejection. The cumulative incidences of acute rejection in the no-induction and basiliximab groups were comparable at 7.8% and 6.4%, respectively. Donor age was markedly higher, and the tacrolimus trough level on the seventh day post-transplantation was significantly lower in the early acute rejection group; however, the significance was lost after adjustment. The incidence of graft loss was higher in the early acute rejection cohort than in the no-rejection cohort (33.3% vs. 3.1%, p<0.001). Early acute rejection was the only independent risk factor for graft failure (HR 10.286, CI 1.944-54.409, p=0.006).
CONCLUSION: Acute rejection within two weeks post-transplantation has been associated with suboptimal graft function in recipients with low immunological risk. Basiliximab does not provide additional advantages in preventing early acute rejection in patients with a low immunological risk on tacrolimus-based immunosuppression.